Home > Press > ULURU Inc. Announces Development Partnership With a Leading Consumer Pharmaceutical Company to Develop a Range of Products.
- Initial development focused on utilizing our nanoparticle elastic gel to improve topical product performance -
ULURU Inc. Announces Development Partnership With a Leading Consumer Pharmaceutical Company to Develop a Range of Products.
ADDISON, TX | Posted on July 11th, 2007
ULURU Inc. (OTC Bulletin Board: ULUR) today announced that it has commenced the development of a range of consumer pharmaceutical products under a development agreement signed with a major consumer pharmaceutical company.
The initial developments are focused on utilizing our nanoparticle
elastic adhesive gel, which offers the potential to significantly extend
the time that a flexible film stays in contact with the skin, to release
active compounds. Under the terms of the agreement ULURU will receive
payments for the development activities and has granted its development
partner a period of exclusivity to enter a potential licensing agreement.
Commenting on the agreement Kerry P. Gray, President and CEO of ULURU
Inc., stated "This is an important validation of our nanoparticle elastic
gel technology. Considerable interest has been expressed in this technology
by both consumer product and dermatology companies as the gel offers the
potential to extend the delivery of actives to the skin surface. Both the
gel technology and our erodible film technology give us the potential to
develop a range of differentiated consumer pharmaceutical products with a
significant period of patent protection. We continue to explore extensions
of our technology applications into the consumer pharmaceutical market as
this offers the potential to accelerate product revenue."
The nanoparticle elastic gel forms a transparent adhesive film that can
be spread on intact skin or superficial non-exudating wounds. The film can
be applied to irregular surfaces such as joints without impairing movement
and deliver active compounds for extended periods of time. Potential uses
of the elastic gel include treatment of acne, psoriasis, skin irritation,
scar management and cold sores.
About ULURU Inc.
ULURU Inc. is an emerging specialty pharmaceutical company focused on
the development of a portfolio of wound management, plastic surgery and
oral care products to provide patients and consumers improved clinical
outcomes through controlled delivery utilizing its innovative transmucosal
delivery system and Hydrogel Nanoparticle Aggregate technology. For further
information about ULURU Inc., please visit our website at
This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as
amended, including but not limited to statements made relating to potential
licensing arrangements, potential uses for our nanoparticle elastic gel
technology, interest expressed in this technology, and the potential for
accelerated product revenue. These statements are subject to numerous risks
and uncertainties, including but not limited to the risk factors detailed
in the Company's Annual Report on Form 10-KSB for the year ended December
31, 2006, Quarterly Report on Form 10-QSB for the quarter ended March 31,
2007 and other reports filed by us with the Securities and Exchange
For more information, please click here
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014
Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014
Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014
Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014
Guo Lab Shows Potential of RNA as Heat-resistant Polymer Material for Nanoarchitectures April 23rd, 2014
PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014
Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014
National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014
Global leader in solar cell manufacturing eyes New York for major expansion outside of Japan: CNSE and Solar Frontier Explore $700 Million Investment, Job Creation in New York State April 22nd, 2014
ASM International Repositions Brand and Introduces New Logo; Looks to Future of Materials Science Innovation: New logo celebrates organizationís history and provides fresh elements for future growth April 21st, 2014
Virus structure inspires novel understanding of onion-like carbon nanoparticles April 10th, 2014
Peer Reviewed and Approved for Science by the the Washington Academy of Sciences April 3rd, 2014